drugset / Trial / NCT04088032
Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the efficacy, safety and tolerability of a combination of immunotherapy and anticancer drugs presurgery in patients with hormone-receptor positive breast cancer.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Outcome
Outcome not reported
Stopped: “Per sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Background | Anastrozole | Other / unclassified | — | — |
| Background | Exemestane | Small molecule | — | — |
| Background | Letrozole | Other / unclassified | — | — |